ARCA biopharma Inc ABIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.75
- Day Range
- $1.76–1.76
- 52-Week Range
- $1.56–2.16
- Bid/Ask
- $1.73 / $1.78
- Market Cap
- $25.52 Mil
- Volume/Avg
- 2,244 / 28,431
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.arcabio.com
Valuation
Metric
|
ABIO
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.69 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ABIO
|
---|---|
Quick Ratio | 58.76 |
Current Ratio | 59.01 |
Interest Coverage | — |
Quick Ratio
ABIO
Profitability
Metric
|
ABIO
|
---|---|
Return on Assets (Normalized) | −11.45% |
Return on Equity (Normalized) | −11.84% |
Return on Invested Capital (Normalized) | −16.72% |
Return on Assets
ABIO
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wkmmmplrz | Tjld | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fkplqqht | Qxjhjd | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wltlrvqff | Fqrtzw | $106.1 Bil | |
MRNA
| Moderna Inc | Tyltngttv | Tmnp | $42.3 Bil | |
ARGX
| argenx SE ADR | Pydwzpbf | Zgyhg | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Thtgrqhr | Drmr | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gnwqfnyd | Bsbzlt | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jcvwclf | Zgkzgrp | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vvchsftg | Wlxmbp | $13.6 Bil | |
INCY
| Incyte Corp | Nxmpzhv | Tlpxmk | $12.8 Bil |